KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Intangibles (2016 - 2025)

Historic Intangibles for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $4.6 billion.

  • Jazz Pharmaceuticals' Intangibles fell 1124.52% to $4.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 1124.52%. This contributed to the annual value of $4.8 billion for FY2024, which is 1222.48% down from last year.
  • Jazz Pharmaceuticals' Intangibles amounted to $4.6 billion in Q3 2025, which was down 1124.52% from $4.8 billion recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Intangibles peaked at $7.6 billion during Q2 2021, and registered a low of $2.1 billion during Q1 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Intangibles had a median value of $5.4 billion in 2023 and averaged $5.5 billion.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Intangibles surged by 23191.65% in 2021 and then tumbled by 2351.07% in 2022.
  • Jazz Pharmaceuticals' Intangibles (Quarter) stood at $7.2 billion in 2021, then decreased by 18.99% to $5.8 billion in 2022, then fell by 6.5% to $5.4 billion in 2023, then decreased by 12.22% to $4.8 billion in 2024, then decreased by 3.99% to $4.6 billion in 2025.
  • Its last three reported values are $4.6 billion in Q3 2025, $4.8 billion for Q2 2025, and $4.7 billion during Q1 2025.